Table 3 Multivariable analysis of progression free survival (PFS) and overall survival (OS) after first autologous transplant (AHCT).

From: In the era of Bortezomib-based Induction, intensification of Melphalan-based conditioning with Bortezomib does not improve Survival Outcomes in newly diagnosed Multiple Myeloma: a study from the Chronic Malignancies Working Party of the EBMT

Risk factor

PFS

OS

 

Group

Follow-up

HR (95% CI)

P

Group

HR (95% CI)

P

Conditioning

Mel200

=<1 year

1

 

Mel200

  

Vel-Mel

=<1 year

1.69 (1.27–2.25)

<0.001

Vel-Mel

1.46 (1.14–1.86)

0.002

Mel200

>1 year

     

Vel-Mel

>1 year

0.88 (0.71–1.10)

0.3

   

Response pre-AHCT

CR

   

CR

  

VGPR

 

1.15 (1.00–1.31)

0.05

VGPR

0.8 (0.65–0.98)

0.034

<=PR

 

1.43 (1.25–1.62)

<0.001

<=PR

1.13 (0.94–1.37)

0.2

Karnofsky at AHCT

<90

   

<90

  

90–100

 

0.95 (0.86–1.05)

0.3

90–100

0.87 (0.75–1.02)

0.09

Age at AHCT (decades)

  

0.99 (0.94–1.06)

0.8

 

1.11 (1.01–1.22)

0.037

ISS

I

   

I

  

II

 

1.27 (1.08–1.49)

0.003

II

1.79 (1.36–2.35)

<0.001

III

 

1.56 (1.33–1.83)

<0.001

III

2.26 (1.72–2.96)

<0.001

FISH

Standard

   

Standard

  

High

 

1.43 (1.18–1.74)

<0.001

High

1.78 (1.33–2.38)

<0.001

  1. Patient age at transplant is in decades. The non-proportional effect of conditioning in PFS was modeled by a step-function of time. Separate hazard ratios were estimated in the follow-up periods 0–1 year and >1 year after AHCT. The effect of conditioning was proportional in OS. Effect estimates are given with 95% confidence intervals. Corresponding p-values are calculated using the Wald test.
Back to article page